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Abstract
Guided by computational analysis, herein we report the design, synthesis and evaluation of four novel diazine-based histone
deacetylase inhibitors (HDACis). The targets of interest (TOI) are analogues of panobinostat, one of the most potent and versatile
HDACi reported. By simply replacing the phenyl core of panobinostat with that of a diazine derivative, docking studies against
HDAC2 and HDAC8 revealed that the four analogues exhibit inhibition activities comparable to that of panobinostat. Multistep
syntheses afforded the visualized targets TOI1, TOI2, TOI3-rev and TOI4 whose biological evaluation confirmed the strength of
HDAC8 inhibition with TOI4 displaying the greatest efficacy at varying concentrations. The results of this study lay the founda-
tion for future design strategies toward more potent HDACis for HDAC8 isozymes and further therapeutic applications for
neuroblastoma.
Introduction
One of the most important posttranslational modifications
involve acetylation/deacetylation of histone proteins by histone
deacetylases (HDACs) [1]. HDACs belong to an important
family of enzymes consisting of 18 isozymes. They control pro-
tein acetylation, which is a change that occurs after translation.
In addition, they regulate gene transcription, cell differentiation,
cell cycle progression and apoptosis by targeting both histone
and non-histone proteins. The balance between acetylation and
deacetylation is pivotal for typical cell function. Abnormal or
increased HDAC expression has been reported in several
human tumors and cancer cell lines [2]. As such, the develop-
ment of novel HDAC inhibitors (HDACis) has become a
rapidly evolving area where targeted inhibition has emerged in
clinical research as a potential therapeutic approach for the
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Figure 1: Chemical structures of the target diazine-based surrogates for the central core of panobinostat.
treatment of various cancers as well as neurodegenerative disor-
ders and immune related diseases [3-5]. Of specific interests are
Class I HDAC isozymes, HDAC2 and HDAC8, which are im-
portant targets in cancer models as both are associated with
high risk diseases such as prostate cancer and neuroblastoma
[6-8]. Compounds such as vorinostat, givinostat and panobino-
stat have been successfully applied as HDAC inhibitors [3].
Among these drugs, panobinostat (Farydak, Novartis) an FDA
approved drug, has been recognized as a pan-deacetylase inhibi-
tor [9,10]. As a hydroxamic acid pan-HDACi, it is zinc-depend-
ent, capable of binding in a bidentate fashion to the zinc-con-
taining catalytic domain of the HDACs, and classified as highly
potent amongst traditional HDACis [11]. According to previous
reports, panobinostat not only induces apoptosis in cells, but
also stimulates cell growth inhibition, and cell-cycle arrest in a
time- and dose-dependent manner. Thus, panobinostat has
demonstrated high therapeutic potential in anticancer efforts.
Although panobinostat offers a versatile approach for the inhi-
bition of cancer cell growth and survival, a lack of selectivity
and bioavailability can cause negative molecular and clinical
effects, specifically in combination therapies.
Despite advances in Class I HDAC inhibition, there remains an
obvious need to develop compounds having better therapeutic
properties as a single-agent therapeutic drug. Our recent
research based on computational studies indicated heterocyclic
cores as suitable surrogates for the central core of the hydroxa-
mate derivative, panobinostat [12]. It should be noted that
TOI3-rev in this article is different from TOI3 in the previous
reporting [12]. Here, the 1,2-diazole ring has been replaced with
that of a pyrimidine core. Given the abundance of literature
regarding analogues having modifications of the indole amine
unit and vinylogous hydroxamic moieties [13-15], the non-
availability of the central core modification stimulated our
interest toward altering the central core to evaluate efficacy. We
found particular interest in the replacement of the phenyl ring
with diazine cores (pyridazines, pyrimidines and pyrazines) as
their docking values were on par with that of the parent mole-
cule, panobinostat (Figure 1). Given that the diazine-containing
compounds are considered to be one of the most important
classes of heterocycles, their presence in a plethora of pharma-
cology and drug molecules motivated us to synthesize these an-
alogues and subject them towards biological evaluation [16-19].
In addition, our envisioned dinitrogen heterocycle cores may
have increased interactions in the binding pockets, and thus
leading to a better therapeutic activity.
Aiming to provide a strategy to address our global objective of
developing single agent therapeutic hydroxamate derivatives,
we began the synthesis of four leading HDAC8 diazine-based
HDACis: TOI1, TOI2, TOI3-rev and TOI4 (Figure 1).
Herein, we provide a summary of the design process followed
by an outline of the multistep synthesis and preliminary biologi-
cal evaluation of each target. HDAC8 was selected for testing
due to its unique structure and multifaceted functional activities
[4,5,20,21]. HDAC8 is also upregulated in neuroblastoma, a
Beilstein J. Org. Chem. 2020, 16, 628–637.
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Figure 2: Docking pose for panobinostat and panobinostat derivatives in the HDAC8 receptor. (a) Overlay of all compounds investigated in this study
in the HDAC8 active site: panobinostat (green), TOI1 (purple), TOI2 (yellow) and TOI4 (grey); (b) TOI3-rev (pink) docking pose in active site; (c) TOI4
(grey) docking pose in the active site.
childhood pediatric cancer, hence considered a drug target for
this cancer subtype [22,23]. Despite a multifaceted array of al-
ternative treatment options for neuroblastoma, some patient
cohorts who are considered high risk at the time of diagnosis
face poor prognosis [24,25]. Recent studies indicated that
HDAC8 inhibition induces differentiated phenotypes and
reduces neuroblastoma growth in vitro and in vivo with few
adverse effects [22]. However, there are very few effective ther-
apeutic options in neuroblastoma that inhibit HDAC8 [26].
Thus, the design of novel HDAC8 inhibitors as potential
neuroblastoma therapeutics could be valuable to expand the
treatment options for this patient population [27]. Therefore, we
sought to focus on the biological evaluation of our proposed in-
hibitors in HDAC8. This study aimed at offering additional
therapeutic options to be used in conjunction with or in place of




Docking analysis is a well-established technique that is utilized
to evaluate interactions in important biological receptors such
as that of HDACs [28-30]. Previously, we implored docking to
predict the interactions between the active sites of HDAC2 and
HDAC8 molecular frameworks with similar structures to that of
panobinostat [12]. In developing such analogues, the hydroxa-
mate tails and indole capping moiety were maintained as both
are essential to binding at the active site of HDAC2 and
HDAC8. Results suggested that TOI1, TOI2, and TOI4 [12]
would be inhibitors exhibiting similar potency as that of panobi-
nostat. The reported −log(Kd) values were 8.93, 8.64 and 8.25,
respectively, with panobinostat possessing a docking score of
8.47. Considering the effects of structural diversity, TOI3-rev
was included in the library and computationally evaluated to de-
termine its potential as an HDAC8 inhibitor. TOI3-rev pos-
sesses a −log(Kd) value of 8.36 suggesting that it too would be
on a par with panobinostat (8.47).
Our previous study showed that the hydroxamate tail of TOI1,
TOI2, and TOI4 formed a bidentate interaction with the Zn2+
ion at the base of the HDAC8 receptor, which is consistent with
the crystal structure of this class of inhibitors in HDACs [31-
34]. Again, our work here extends the investigation focusing on
HDAC8 due to the need for novel neuroblastoma therapeutics.
Each compound was also shown to have two parallel-displaced
π–π interactions, one with Phe-152 and the other with Phe-208.
The mode of binding for each compound was similar to panobi-
nostat in HDAC8 (Figure 2). Two differences were however
observed in the mode of binding of TOI4. It was shown that the
pyridazine ring did not lay as planar in the gorge as the pyrazine
and pyrimidine rings of TOI1 and TOI2, respectively. The
indole ring of TOI4 was also contorted upward, forming a
T-shaped π–π interaction with Phe-207 while both the indole
rings of TOI1 and TOI2 were shown to be flipped downward
forming a T-shaped π–π interaction with Phe-208.
TOI4 is the only diazine compound having two nitrogens
directly next to each other in the core ring structure. The
nitrogen atoms in the pyridazine ring are positioned so that they
do not sit in the center of the phenyl rings of Phe-152 or Phe-
208. This results in the pyridazine ring of TOI4 shifted closer
to the side of the gorge having Phe-152 compared to the other
Beilstein J. Org. Chem. 2020, 16, 628–637.
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Figure 3: General building blocks for the visualized targets.
Scheme 1: Reaction conditions: a) MeOH, H2SO4 (5 drops), MS 4 Å (2 pieces), 68 °C, 8 h, 81%; b) DIBAL-H (1.2 equiv), 6 h, −78 °C, THF, 78%;
c) phosphorane 8 (2.0 equiv), THF, 8 h, 60 °C, 72%; d) SeO2, dioxane, 110 °C, 8 h, 61%; e) indolamine 10 (1.1 equiv) DCE, sodium triacetoxyboro-
hydride (STAB, 1.1 equiv), TEA (2 equiv), rt, 63%; f) NaOH at −10 °C, NH2OH·H2O at −10 °C, MeOH , rt, 12 h, 55%.
derivative (Figure 2). This shift allows for the indole ring of
TOI4 to fit in a small hydrophobic pocket at the surface, which
is created by the phenyl ring of Phe-207. Like the previously
studied compounds (TOI1, TOI2, and TOI4), TOI3-rev is also
shown to bind to the HDAC8 receptor by forming a bidentate
interaction with the Zn2+ ion. TOI3-rev, like that of TOI1,
TOI2, and TOI4 produces two parallel-displaced π–π interac-
tions with Phe-152 and Phe-208 (Figure 2). The pyrimidine ring
of TOI3-rev also lays planar in the gorge similar to the
pyrazine and pyrimidine rings of TOI1 and TOI2. The indole
ring of TOI3-rev is tilted downward forming a T-shaped π–π
interaction with Phe-208.
In review of the computational results, the inclusion of the
nitrogen atoms in the core ring structure of panobinostat pro-
duced compounds with predicted binding affinities similar to
panobinostat. Thus, aiming to develop improved compounds to
effectively target HDAC8, the synthesis of TOI inhibitors and
their evaluation was undertaken.
Synthesis
Equipped with molecular targets achieved via theory, the syn-
thesis of the hypothesized compounds commenced with com-
mercially available starting materials (Figure 3). The central
core building blocks for TOI1, TOI2, TOI3-rev and TOI4
were selected based on their ability to tether the indole amine
and the zinc binding group in a para-relationship to each other.
Initial efforts focused on synthesizing analogue TOI1
(Scheme 1). Acid 1 was converted to the corresponding methyl
ester 5 via esterification reaction using methanol mediated by
sulfuric acid under heating conditions to provide the compound
Beilstein J. Org. Chem. 2020, 16, 628–637.
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in 81% yield. The methyl ester 5 was reduced to aldehyde 6
using DIBAL-H at −78 °C. While TLC analysis revealed com-
plete conversion of the ester to aldehyde, the isolated yield was
poor (20%). The obstacle was overcome by using a modified
Fieser work-up procedure to yield the aldehyde 6 in high yield,
78%. Then, aldehyde 6 was converted to the α,β-unsaturated
trans-ester 7 through a Wittig reaction with the phosphorane
synthon 8, which was derived from ethyl bromoacetate at 60 °C
for 8 h in THF in 72% yield. The exclusive formation of the
trans-isomer was confirmed by 1H NMR studies, namely the
presence of the olefin at δ 7.00 and 7.71 with a J value of 15 Hz
(Supporting Information File 1, Figure S3).
Next, oxidation of the methyl group of 7 under SeO2 condi-
tions at 110 °C provided the ethyl acrylate aldehyde 9 in 61%
yield. The next step involved the crucial reductive amination
reaction between aldehyde 9 with indolamine 10, which had
been obtained via Fischer indole synthesis – the reaction of
phenylhydrazine with 5-chloro-2-pentanone [35]. Initial reduc-
tion attempts using sodium triacetoxyborohydride (STAB) as
the reducing agent provided predominantly starting material and
negligible potential product as monitored by TLC. However,
addition of 2 equivalents of triethylamine to the reaction mix-
ture facilitated the formation of the product, compound 11 in
63% yield. The product was confirmed by 1H NMR and
13C NMR as shown in Supporting Information File 1.
Finally, the ethyl ester 11 was converted to the hydroxamic acid
derivative, TOI1 using the bidentate nucleophile hydroxyl-
amine either under neutral or basic conditions [36,37]. We first
explored neutral conditions where aqueous hydroxylamine was
added to compound 11 in methanol, and a predominant polar
spot was observed by TLC. However, the isolated product was
not the expected TOI1, as 1H NMR revealed two new peaks at
δ 4.53 and 2.66 ppm (Supporting Information File 1, Figure
S36) presumably indicating that a favorable Michael addition
followed by intramolecular cyclization or vice versa provided
compound 12, which was validated by 13C and DEPT NMR
studies (Supporting Information File 1 Figures S37and S38).
Marred with these observations, compound 11 was treated with
aqueous hydroxylamine in the presence of strong base (i.e.,
10 equivalents of methanolic sodium hydroxide or aqueous so-
dium hydroxide) at 0 °C. The reaction was monitored by TLC
and it revealed that methanolic sodium hydroxide provided a
cleaner reaction than aqueous sodium hydroxide conditions.
The reaction mixture was quenched with a saturated ammoni-
um chloride solution at 0 °C after 12 h, the solvent was evapo-
rated, and the compound was subjected to reversed-phase
column chromatography using C-18 silica gel. After initial un-
successful purification protocols with water/ACN or water/THF
Scheme 2: Reaction conditions: a) boronic acid 15 (1.3 equiv),
PdCl2(PPh3)2 (0.1 equiv), dioxane/H2O (3:1), Na2HPO4 (2.0 equiv),
TEA (4.0 equiv), 90 °C, 15 h, 55% for 16 and 71% for 18; b) SeO2 ,
different conditions, 0%; c) SeO2 (2.0 equiv), dioxane, 110 °C, 12 h,
54%.
solvent systems, we identified an optimized water/methanol
mixture to provide the pure product TOI1 in 55% yield. The
isolated compound was thoroughly characterized by spectros-
copic techniques.
Having successfully establish reaction conditions for the syn-
thesis of TOI1, we then focused our efforts on the generation of
regioisomers TOI2 and TOI3-rev, respectively. Initial attempts
to oxidize the methyl group at the benzylic position in starting
materials 2 and 3 to provide the corresponding aldehyde com-
pounds 13 and 14 failed, despite using rigorous reaction condi-
tions of SeO2 or alternative strong oxidizing agents (e.g., MnO2
and oxone). Thus, we considered the critical role of the elec-
tronic effects of the nitrogen atoms on this cyclic substrate, and
then we revised our synthetic strategy by a) tethering an alkene
functional group on the aromatic ring and b) then conducting
the oxidation of the benzylic group to afford the aldehyde prod-
uct. Towards this end, we performed a Suzuki coupling reac-
tion between boronic acid 15 with chloro compound 2
(Scheme 2). To the best of our knowledge, there is no report of
a Suzuki coupling reaction using boronic acid 15 in the litera-
ture. However, we generated this required boronic acid from the
corresponding methyl propiolate [38].
Beilstein J. Org. Chem. 2020, 16, 628–637.
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Scheme 3: Reaction conditions: a) 5-bromo-2-chloropyrimidine (1 equiv), ethyl formate (1.5 equiv), THF (20 mL), n-butyllithium (0.6 equiv, 2.5 M) in
hexane, −100 °C, 2 h, 42%; b) boronic acid (1.3 equiv), PdCl2(PPh3)2 (0.1 equiv), dioxane/water (8:2), Na2HPO4 (2.0 equiv), TEA (4.0 equiv), 95 °C,
15 h, 40%; c) indolamine 10 (1.1 equiv) DCE, STAB (1.0 equiv), TEA (2 equiv), rt, 61% for 22, 68% for 23; d) NaOH at −10 °C, NH2OH·H2O at
−10 °C, MeOH, rt, 12 h, 49% for TIO2 and 51% for TIO3-rev.
Next we investigated reaction conditions for the reaction of
compound 2 with boronic acid 15 using different variables
(Supporting Information File 1, Table S1). Gratifyingly, after
surveying several reaction conditions, we successfully obtained
the desired product 16 in 35% yield using PdCl2(PPh3)2 and
Na2HPO4 as the base in a dioxane/water system under heating
conditions of 90 °C.
To improve the overall chemical yields, we evaluated several
organic bases and found that TEA (4.0 equiv) improved the
yield to 55%. This success was attributed to the improved in-
creased solubility of TEA in the reaction mixture under heating
conditions. In parallel, similar reaction conditions were used for
compound 3 and the final coupled product 18 was obtained in
71% yield. The product was confirmed by the expected chemi-
cal shift at δ 6.50 and 7.54 ppm with a J value of 15 Hz for
compound 16 (Supporting Information File 1, Figure S7) and δ
6.57 and 7.63 ppm with a J value of 15 Hz for compound 18
(Supporting Information File 1, Figure S9) as inferred by 1H
NMR analysis.
The resulting Suzuki-coupled products 16 and 18, were subject-
ed to benzylic oxidation expecting the olefin functionality
would facilitate the corresponding aldehydes 17 and 19, respec-
tively. Surprisingly, the methyl group in compound 16 did not
undergo oxidation under SeO2 conditions as observed for TOI1
whereas under the same reaction conditions, compound 18
readily underwent oxidation to yield compound 19 in 54%
yields.
Confounded by this observation, extensive experimentation
varying solvent and temperature were evaluated, but none were
fruitful. Alternatively to synthesize compound 17, we adapted
the strategy as depicted in Scheme 3. Compound 20 was con-
verted into compound 17 via intermediate 21 using a previ-
ously reported literature procedure [39]. The intermediate 21
was then subjected to the Suzuki reaction using conditions
already developed to provide the ester aldehyde 17 in overall
yield of 16% for two steps. Having identified synthetically suit-
able conditions for compound 17, we scaled up the reaction to
complete the final two steps, the reductive amination reaction
and the hydroxamic acid preparation. Using the same reaction
conditions developed for TOI1, we proceeded with precursors
22 and 23, which were obtained in 61% and 68% yield, respec-
tively. The desired hydroxamic acid TOI2 and TOI3-rev were
obtained in 49% and 51% yield, respectively, after C18 silica
gel purification procedure using a methanol/water (1:1) solvent
system.
Finally, we focused our efforts towards the synthesis of the last
analogue TOI4. From the above observations, we hypothesize
that successful synthesis of TOI4 would rely on generating the
key intermediate aldehyde 25 (Scheme 4).
Initially, we explored the Suzuki coupling reaction for sub-
strate 4. Gratifyingly, the reaction product 24 was produced in
41% yield from our developed synthetic strategy. Then, com-
pound 24 was subjected to an SeO2 oxidation reaction. The oxi-
dation reaction was performed at 110 °C for 16 h to furnish the
Beilstein J. Org. Chem. 2020, 16, 628–637.
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Scheme 4: Reaction conditions: a) boronic acid 15 (1.3 equiv), PdCl2(PPh3)2 (0.1 equiv), dioxane/H2O (8:2, Na2HPO4 (2.0 equiv), TEA (4.0 equiv),
95 °C, 15 h, 41%; b) SeO2 (2.0 equiv), dioxane , 110 °C, 16 h, 52%; c) indolamine 10 (1.1 equiv), DCE, STAB (1.0 equiv), TEA (2 equiv), rt, 38%; d)
NaOH at −10 °C, NH2OH·H2O at −10 °C, MeOH, rt, 12 h, 44%.
Table 1: Percent inhibition of HDAC8 by hydroxamate inhibitors.
compound
concentration
100 µM 10 µM 1 µM
panobinostat (n = 4)a 100 ± 0.0 100 ± 0.0 89 ± 13.4
TOI1 (n = 4) 100 ± 0.0 90 ± 21.1 44 ± 11.5
TOI2 (n = 4) 79 ± 8.1 75 ± 13.4 23 ± 26.9
TOI3-rev (n = 4) 89 ± 7.0 75 ± 26.9 37 ± 18.1
TOI4 (n = 4 @ 100 and 10 µM,
n = 3 @ 1 µM)
93 ± 8.1 89 ± 13.4 65 ± 21.4
TCAb 93 ± 14.0
an = number of replicates for the assay; btrichostatin A (TCA) as an inhibitor control.
aldehyde 25 in 52% yield. Next, successful coupling of the
aldehyde 25 with indolamine 10 yielded the expected product
26 in 38% yield. Compound 26 was converted to hydroxamic
acid TIO4 in 44% yield under NaOH conditions in methanol
and purified using C18 column chromatography. All the final
compounds were thoroughly characterized by NMR and mass
spectrometry (see Supporting Information File 1).
Having successfully synthesized the targets TOI1 to TOI4, our
next aim was to evaluate them biologically.
Inhibition assay
The biochemical evaluation of the proposed inhibitors TOI1,
TOI2, TOI3-rev, and TOI4 was performed to experimentally
determine the potency of HDAC8 inhibition. The obtained
results, as shown in Table 1, aligned with the predicted compu-
tational studies. In a homogeneous fluorogenic assay, the
HDAC activity is quenched with a fluorescent dye that is teth-
ered to an acetyllysine-containing peptide. If the acetyl moiety
of the fluorophore is enzymatically hydrolyzed by HDAC8, it
will produce a strongly fluorescent signal at 360 nm. Table 1
shows the percentage of HDAC8 inhibition at 100, 10, and
1 µM concentration of the designed inhibitors and panobinostat.
All compounds displayed HDAC8 inhibition as predicted by
our computational studies [12]. Complete inhibition of HDAC8
was observed for panobinostat at 100 µM or 10 µM concentra-
tion, while only 89% inhibition was recorded at 1 µM concen-
tration. The in vitro IC50 values for panobinostat against
HDAC8 have been shown to be 277 nM [11]. In vivo studies
measuring the IC50 values of panobinostat have also been
performed, however, since panobinostat is a pan-DAC inhibitor
it has been difficult for researchers to specifically correlate
its IC50 value for HDAC8 in a physiological system [40]. Theo-
retical studies predicted TOI1 as the most potent inhibitor
over TOI2, TOI3-rev, and TOI4. TOI1 was shown to be
the most potent inhibitor designed in this study producing
100% inhibition at a 100 µM, 90% inhibition at a 10 µM,
and 44% at a 1 µM concentration. At a 100 µM concentration,
TOI2, TOI3-rev and TOI4 inhibited 79%, 89%, and 93%
of HDAC8 activity, respectively. Strong inhibition was
seen at a 10 µM concentration for all inhibitors. At a concentra-
tion of 1 µM all inhibitors showed less inhibition of HDAC8
than panobinostat. It was noted that TOI2 and TOI3-rev
produced similar inhibition results against HDAC8. Both of
Beilstein J. Org. Chem. 2020, 16, 628–637.
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these inhibitors have pyrimidine rings in the core; thus, the data
suggests that while this ring structure did produce inhibition, it
was not as effective as the inclusion of a pyrazine ring.
This finding is consistent with our computational data which
demonstrated that TOI1 would slightly outperform TOI2 and
TOI3-rev.
It is interesting to note that TOI1, which was shown to be better
than TOI4 at the 100 µM level, was less potent than TOI4 at
low concentration (1 µM). TOI4, which was predicted to be
slightly less potent than TOI1, TOI2, and TO3-rev computa-
tionally was revealed via experiment to be a better inhibitor
than TOI2 and TOI3-rev. The result was observed presumably
due to a variation in the binding mode for TOI4 that differs
from that of TOI1, TOI2, and TOI3-rev. TOI4 was shown to
observe a slightly different orientation of the core heterocyclic
ring as well as a change in the orientation of the terminal indole
ring. It is not clear if this difference in binding mode affected
the ability of TOI4 to maintain a higher potency at lower con-
centrations. However, this observation does raise an interesting
question: “Are certain modes of binding more effective at dif-
ferent concentrations and if so how can this be accurately
modelled computationally?” Taken together, this data indicates
that while TOI1 is the best inhibitor of the four compounds
presented herein, TOI4 remains effective against HDAC8 even
at lower concentrations.
Conclusion
Our investigation provides a successful synthetic strategy
towards four new analogues of panobinostat having diazines as
the central core and details the results of their biochemical eval-
uation. Computational data corroborated that the substitution of
benzene in the molecular framework of panobinostat for a
nitrogen-containing heterocycle in the core ring structure would
enhance the pharmacological properties while maintaining the
level of HDAC8 inhibition. The targets TOI1–4 were synthe-
sized from commercially available starting materials in moder-
ate yields. The synthesized compounds displayed potent activi-
ty against HDAC8; thus, emphasizing the advantages of drug
design on a theoretical basis. These efforts led to the design of
potential analogues that warrant further studies to develop ther-
apeutic agents for neuroblastoma. Future research will be aimed
at investigating the HDAC class specificity of these designed




Reagents and solvents were purchased from commercial
sources and used without further purification unless otherwise
specified. Tetrahydrofuran (THF), ether, dichloromethane
(DCM), and dimethylformamide (DMF) were degassed in 20 L
drums and passed through two sequential purification columns
(activated alumina; molecular sieves for DMF) under a positive
argon atmosphere. Thin-layer chromatography (TLC) was per-
formed on SiO2-60 F254 aluminum plates with visualization by
ultraviolet (UV) detection at 254 nm or staining. Flash column
chromatography was performed using Purasil SiO2-60,
230–400 mesh from Whatman. NMR spectra were recorded on
a BRUKER AV500 spectrometer (operating at 500 MHz for 1H
and 125 MHz for 13C acquisitions). Chemical shifts were re-
ported as ppm relative to the solvent residual peak (CHCl3:
7.26 ppm for 1H, 77.2 ppm for 13C). Data are reported as
follows: chemical shifts, multiplicity (s = singlet, d = doublet,
t = triplet, q = quartet, quint = quintet, m = multiplet,
br = broad), coupling constant J (Hz), and integration. High-
resolution mass spectra were recorded using an ESI–TOF mass
spectrometer (Agilent 6220 Time-of-Flight), gas temperature –
350 °C, drying gas (N2) – 8.0 L/min, mobile phase(s): metha-
nol with 0.1% formic acid, flow rate: 0.2 mL/min, sample prep-
aration: The sample was dissolved in 1 drop of chloroform and
diluted with 1 mL methanol.
Additional chemical synthesis details can be found in Support-
ing Information File 1.
HDAC8 enzymatic activity assay
A fluorogenic assay (BPS Bioscience, catalog # 50008) was
performed to evaluate the inhibition potential of the designed
inhibitors. The assay was carried out using the supplier’s
instructions. TOI1, TOI2, TOI3-rev, TOI4, and panobinostat
were evaluated at concentrations of 100 µM, 10 µM, and 1 µM
in a 96 well plate. Trichostatin A (TCA), which was used as an
inhibitor control, was also evaluated at 100 µM. The blank con-
sisted of HDAC assay buffer without the addition of inhibitor or
HDAC8, while the positive control consisted of HDAC8 with-
out inhibitor added. The substrate concentration was 5 µM, and
HDAC8 concentration per well was 4 ng/µL. The reaction was
initiated by addition of enzyme. The fluorogenic substrate was
excited at 360 nm and the emission signal was detected at
460 nm using a Biotek Synergy HTX multimodal plate reader
after incubation for 30 minutes.
Preparation of the HDAC8 receptor for
docking
The HDAC8 crystal structure (protein database pdb: 1W22)
[32] was utilized as the docking receptor for all compounds.
This receptor is crystalized as a dimer thus only the A chain
was prepared for docking using Sylbyl-X 2.1. A protocol
defining the regions of hydrogen donor, acceptor and hydro-
phobic character was created using the SFXC protocol [41-43].
The Zn2+ ion which is known to be essential in the hydroxa-
Beilstein J. Org. Chem. 2020, 16, 628–637.
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mate class of HDAC inhibitors was included in the preparation
of the receptor.
Preparation of inhibitor compounds for
docking
Compounds were drawn in ChemDraw and the converted for
2D to 3D using Marvin Sketch. The energy gradient optimiza-
tion method was used to perform an initial minimization in
Marvin Sketch. A full structural minimization was performed in
UCSF Chimera [44] using conjugate gradient followed by
steepest decent. In Sybyl-X multiple conformers of each poten-
tial inhibitor compound were created for docking analysis using
the prep protocol Docking >1 parameter.
Molecular docking of inhibitors in the HDAC8
receptor
The inhibitor candidates were docked into the receptor using the
Surflex-Dock Geom (SFXC) protocol [41-43] to evaluate the
binding affinity of the ligand for the HDAC8 receptor. The
C-scoring method was used to calculate these binding affinities
and binding scores are given in −log10(Kd) values [45]. Docking
simulations where ran considering conformers at pH 7 to simu-
late the physiological conditions where the pH is 7.4. Results
were analyzed in both Sybyl-X and UCSF Chimera.
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